They have also announced the addition of 100 snakes to the existing milking line to increase venom production for the upcoming international orders from India and China.
"We are at an amazing inflection point for the Company," commented Rik J. Deitsch, Chairman and CEO of Nutra Pharma Corporation.
"Over the past few months, we have dramatically reduced costs, paid down debt and recapitalized the share structure of the Company," he continued.
"Now we need to focus on increasing sales for our OTC products, Nyloxin and Pet Pain-Away. This also requires us to scale up our raw material supplies and production facilities. The growth-limiting material for Nutra Pharma is cobra venom, the active ingredient in our OTC products.
"We need to make sure that we have an adequate supply of validated material to meet our future production needs. With the recently announced expansion into India and China, we realize that we will need to grow exponentially to meet these expected product orders in the coming months. The expansion of the reptile facilities ensures that we can grow apace with the increasing orders," he concluded.
Nyloxin is an over-the-counter (OTC) pain reliever clinically proven to treat moderate to severe (Stage 2) chronic pain. Nyloxin is currently available as an oral spray for treating back pain, neck aches, headaches, joint pain, migraines, and neuralgia, and as a topical gel for treating joint pain, neck pain, arthritis pain, and pain from repetitive stress.
In addition to its everyday strength formulation, Nyloxin is also offered in an extra strength formula for more advanced, Stage 3, chronic pain.